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De novo CTBP1 variant is associated with
decreased mitochondrial respiratory chain
activities
ABSTRACT
Objective: To determine the genetic etiology of a young woman presenting an early-onset, pro-
gressive neurodegenerative disorder with evidence of decreased mitochondrial complex I and
IV activities in skeletal muscle suggestive of a mitochondrial disorder.
Methods: A case report including diagnostic workup, whole-exome sequencing of the affected
patient, filtering, and prioritization of candidate variants assuming a suspected autosomal reces-
sive mitochondrial disorder and segregation studies.
Results: After excluding candidate variants for an autosomal recessive mitochondrial disorder, re-
evaluation of rare and novel heterozygous variants identified a recently reported, recurrent path-
ogenic heterozygous CTBP1 missense change (c.991C.T, p.Arg331Trp), which was confirmed
to have arisen de novo.
Conclusions: We report the fifth known patient harboring a recurrent pathogenic de novo
c.991C.T p.(Arg331Trp) CTBP1 variant, who was initially suspected to have an autosomal
recessive mitochondrial disorder. Inheritance of suspected early-onset mitochondrial disease
could wrongly be assumed to be autosomal recessive. Hence, this warrants continued re-
evaluation of rare and novel heterozygous variants in patients with apparently unsolved sus-
pected mitochondrial disease investigated using next-generation sequencing. Neurol Genet
2017;3:e187; doi: 10.1212/NXG.0000000000000187
GLOSSARY
ATP5 adenosine triphosphate;COX5 cytochrome c oxidase;GVGD5Grantham Variation with GranthamDeviation;MEF5
mouse embryonic fibroblast; mtDNA 5 mitochondrial DNA; SDH 5 succinate dehydrogenase; WES 5 whole-exome
sequencing.
Mitochondrial respiratory chain disorders are among the most common early-onset metabolic dis-
orders with an estimated minimum point prevalence of 1 in 5,000 live births.1 Early-onset respi-
ratory chain disorders are characterized by extreme clinical, molecular, and genetic heterogeneity due
to pathogenic mitochondrial DNA (mtDNA) or nuclear gene variants affecting proteins essential for
mitochondrial functions. The diagnosis of suspected mendelian mitochondrial disorders is especially
challenging given that an estimated 1,200 mitochondrial proteins are encoded by the nuclear
genome. Whole-exome sequencing (WES) has been widely used as a cost-effective tool for the
diagnosis of suspected mendelian, early-onset mitochondrial respiratory chain disorders.2–5 How-
ever, secondary respiratory chain defects in skeletal muscle have also been described in other
neuromuscular and neurologic disorders due to pathogenic variants of genes encoding nonmito-
chondrial proteins,6,7 providing additional challenges to candidate variant prioritization.
We describe a young woman presenting an early-onset, progressive neurodegenerative disor-
der with decreased mitochondrial complex I and IV activities in skeletal muscle. Using WES, we
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identified a recurrent pathogenic de novo het-
erozygous CTBP1 variant previously associ-
ated with an early-onset neurologic disorder.8
We highlight the challenges of variant priori-
tization in a patient who was initially sus-
pected to have an autosomal recessive
mitochondrial disorder.
METHODS Muscle histopathological, biochemical, and
genetic studies. Diagnostic muscle biopsy was performed accord-
ing to standard procedures. Muscle biopsy was subjected to cyto-
chrome c oxidase (COX) and succinate dehydrogenase (SDH)
histochemical reactions.9 Mitochondrial respiratory chain complex
activities (complexes I-IV) relative to citrate synthase were measured
in the skeletal muscle homogenate as previously described.10 Whole
mitochondrial genome sequencing was performed to exclude patho-
genic point mutations and small insertions or deletions, while diag-
nostic quantitative real-time PCR and long-range PCR assays were
performed for mtDNA quantification and detection of rearrange-
ments, according to standard protocols.
Whole-exome sequencing, analysis, and interpretation.
Exome capture was attained using the Illumina TruSeq 62 Mb
capture kit, sequenced using the Illumina HiSeq 2000 system
in 100 base pair (bp) reads, and aligned to the human reference
genome (UCSC hg19). Variants with a minor allele frequency
$0.01 (1%) from 378 in-house controls and external variant
databases including the Exome Aggregation Consortium,
National Heart, Lung, and Blood Institute Exome Variant Server
(Exome Sequencing Project), and 1000 Genomes Project were
excluded. Autosomal recessive (compound heterozygous or
homozygous) variants in nuclear genes encoding mitochondrial-
localized proteins were prioritized. Autosomal recessive variants of
all nuclear genes were next examined, followed by examination of
rare and novel heterozygous variants. PolyPhen-2, SIFT, and
Align Grantham Variation with Grantham Deviation (GVGD)
were used to assess the pathogenicity of candidate variants.
Sanger sequencing validation. Candidate variants were vali-
dated by Sanger sequencing using standard protocols.2 Custom
forward and reverse primers were designed for all exons and in-
tronic regions of EARS2 (NM_001083614) and exon 9 of
CTBP1 (NM_001012614).
RESULTS Case report. This female patient was born
to nonconsanguineous parents following a normal
pregnancy. Very early development was considered
normal though, while the patient was able to sit inde-
pendently at 8 months, she disliked being placed
prone and never acquired the ability to crawl. She
did manage to walk with hand-holding support at
the age of 16 months but generalized hypotonia and
weakness meant that independent ambulation was
never achieved and she started to use a wheelchair.
Fine motor skills were variable in that she could turn
the pages of a book and hold a crayon, but had dif-
ficulty drawing. Language acquisition was limited to
a few words in early life and these were lost by the age
of 4 years. Scoliosis, requiring corrective surgery, had
developed by 10 years, and at 14 years, she had
pneumonia with cardiorespiratory arrest. Following
successful resuscitation, she was notably weaker and
dysphagic, becoming dependent on a percutaneous
endoscopic gastrostomy tube for feeding. Brain MRI
about 2 years prior to this event had revealed mild
cerebellar and brainstem atrophy, but no neuro-
imaging was performed afterward. Clinical examina-
tion, at the age of 16 years, revealed a young woman
with sunken eyes and thin tapering fingers. Move-
ments of her limbs and face were infrequent and slow.
Lower limbs were cold and edematous with livedo
reticularis of the overlying skin. Although her muscle
tone was generally low, she had increased tone at the
elbows, wrists, knees, and ankles with contractures
of the wrists and elbows. There was a marked spinal
scoliosis, and muscle mass was generally decreased.
At 16 years of age, she died of acute respiratory
failure.
Her family history was unremarkable for neuro-
logic disorders; she had 1 unaffected younger sibling.
Diagnostic Sanger sequencing of PLA2G6
(NM_003560) and APTX (NM_001195251) per-
formed at another center was negative for pathogenic
or likely pathogenic variants.
A skeletal muscle biopsy showed histopathologic
abnormalities including variation in muscle fiber size,
occasional internal nuclei, and evidence of denerva-
tion atrophy. These were accompanied by increasing
accumulation of fibroadipose connective tissue and
patchy lipid accumulation within the muscle, with
excess lipid also surrounding the muscle. Oxidative
enzyme histochemistry showed patchy loss of COX
activity and clumped SDH reactivity; unfortunately,
sequential COX-SDH histochemistry was not per-
formed. Biochemical analysis of mitochondrial respi-
ratory chain activities showed decreased complex I
(57% of control) and IV (35% of control) activities,
with sparing of the complex II activity (figure, A).
Based on these findings, whole mitochondrial
genome sequencing was performed but failed to
detect known pathogenic or likely pathogenic var-
iants. Quantitative real-time PCR and long-range
PCR assays also excluded mtDNA depletion and
mtDNA rearrangements.
Whole-exome sequencing analyses. Informed parental
consent was obtained, and WES was performed.
Anticipating a possible autosomal recessive mito-
chondrial disorder, nuclear genes encoding
mitochondrial-localized proteins were prioritized.
However, no likely candidate variants were iden-
tified, and inspection of all rare autosomal recessive
variants did not reveal persuasive candidates. A
rare heterozygous missense variant (c.452A.G,
p.Lys151Arg) in EARS2 (NM_001083614) encoding
mitochondrial glutamyl-transfer RNA synthetase was
identified; recessive pathogenic EARS2 variants cause
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the mitochondrial disorder leukoencephalopathy with
thalamus and brainstem involvement and high
lactate.11 However, the c.452A.G p.(Lys151Arg)
variant was not previously reported as pathogenic.
In addition, Sanger sequencing of all exons and
intronic regions of EARS2 did not identify a second
candidate variant. Examination of WES read cov-
erage also did not disclose copy number variants or
rearrangements involving EARS2.
Inspection of rare and novel heterozygous variants
that were predicted to be damaging to protein func-
tion revealed a c.991C.T p.(Arg331Trp) missense
change in CTBP1 (NM_001012614.1). Following
the report of 4 patients sharing the identical hetero-
zygous CTBP1 variant that arose de novo in each
case,8 Sanger sequencing with extracted blood DNA
from our patient and her parents confirmed that the
c.991C.T p.(Arg331Trp) variant had arisen de no-
vo or 1 parent was low level mosaic (figure, B). The
c.991C.T p.(Arg331Trp) variant was absent from
our in-house exomes and external databases, affected
a highly conserved residue, and was predicted to be
deleterious by PolyPhen-2, SIFT, and Align GVGD
(figure, C).
DISCUSSION We performed WES of a woman pre-
senting an early-onset, progressive neurodegenerative
disorder and suggested mitochondrial etiology on the
basis of decreased respiratory chain activities of
complexes I and IV, with sparing of the complex II
activity, in a muscle biopsy. Suspecting an autosomal
recessive disorder of mitochondrial translation, fil-
tering and interpretation of variants in nuclear genes
encoding mitochondrially targeted proteins failed to
Figure Biochemical and molecular genetic characterization of the de novo c.991C>T p.(Arg331Trp) CTBP1
variant
(A) Mitochondrial respiratory chain activities normalized to citrate synthase for complexes I-IV in patient’s skeletal muscle
(green) compared with controls (red). Asterisk denotes decreased complex I and IV activities. (B) Family pedigree and Sanger
sequencing confirming that the c.991C.T p.(Arg331Trp) variant arose de novo. (C) Multiple sequence alignment demon-
strating high conservation of the Arg331 residue.
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identify likely candidates. Only after the evaluation of
rare and novel heterozygous variants was a previously
reported pathogenic c.991C.T p.(Arg331Trp)
CTBP1 variant identified and confirmed to have
arisen de novo. All 4 previously reported patients
presented with comparable phenotypes of hypotonia,
ataxia, severe developmental delay, intellectual dis-
ability, and problems with weight gain.8 Similarly,
our patient had generally low muscle tone, develop-
mental regression, severe intellectual disability, and
was nonambulatory. Cerebellar atrophy was also
noted in our patient and 2 reported patients. Of
interest, all previously described patients also had
striking tooth enamel defects manifesting as hypo-
plasia or discoloration. By contrast, our patient had
normal teeth on clinical examination, although there
was no comment on the enamel.
CTBP1 encodes C-terminal binding protein 1
(CtBP1), a transcriptional corepressor first identified
as an E1A oncogene binding protein,12 but has also
been shown to associate with DNA-specific repressors
during human development and tumorigenesis,13,14
thereby regulating gene expression and DNA repair.
Although CtBP1 does not localize to mitochondria, it
has been identified as a key regulator of mitochondrial
function and morphology.15 Knockout of Ctbp1 in
mouse embryonic fibroblasts (MEFs) resulted in
elongated mitochondria, swollen cristae, and decreased
cellular adenosine triphosphate (ATP), oxygen con-
sumption, and mitochondrial membrane potential.15
Altered mitochondrial function and morphology were
attributed to transcriptional repression of Bcl-2-
associated X protein (Bax) by CtBP1. BAX has been
demonstrated to be essential for Drp1-dependent fis-
sion,16 while also regulating mitochondrial-dependent
apoptosis in response to glucose deprivation, for which
its expression is modulated by association of CtBP1
with the BAX promotor.15 When Bax and Ctbp1 were
knocked out together in MEFs, this led to increased
ATP production, oxygen consumption rate, and mem-
brane potential, confirming a role for CtBP1 in main-
taining mitochondrial functions.
The de novo c.991C.T p.(Arg331Trp) CTBP1
variant occurs in the PLDLS C-terminal binding
cleft, which is required for the recruitment of
DNA-binding factors and components of the CtBP1
corepressor complex.17 Decreased complex I and IV
activities in skeletal muscle of our patient suggests
that BAX expression is altered by mutated CtBP1,
with the c.991C.T p.(Arg331Trp) variant acting
in a dominant-negative mechanism to disrupt mito-
chondrial function. CtBP1 may also regulate the
expression of additional nuclear genes involved in
mitochondrial functions, including nuclear genes en-
coding essential mitochondrial protein synthesis
machinery. The original description of 4 patients
with a recurrent de novo CTBP1 variant did not
report respiratory chain defects in skeletal muscle,
although one patient was investigated for “pathogenic
mitochondrial mutations”.8 As yet, it is unclear
whether mitochondrial dysfunction contributes to
the pathogenesis of this disorder or is a secondary
consequence. Therefore, future studies of mitochon-
drial function and morphology in tissue from affected
patients could provide further insights into the path-
ologic mechanisms involved.
Pathogenic de novo heterozygous variants have been
widely associated with early-onset phenotypes that
include autism and epileptic encephalopathies.18,19
By contrast, reported de novo variants associated with
early-onset mitochondrial disorders are rare. Recently, 5
patients sharing a de novo c.1582C.T p.(Arg528Trp)
ATAD3A variant with global developmental delay,
hypotonia, optic atrophy, axonal neuropathy, and
hypertrophic cardiomyopathy were identified.20 In addi-
tion, de novo c.239G.A p.(Arg80His) and c.703C.G
p.(Arg235Gly) SLC25A4 variants were reported in 7
patients with neonatal-onset respiratory insufficiency
and severe mtDNA depletion in skeletal muscle.21 Can-
didate variant filtering strategies of early-onset mito-
chondrial disorders investigated using next-generation
sequencing have typically prioritized autosomal recessive
or X-linked variants in nuclear genes encoding
mitochondrial-localized proteins.2–5 Although the
diagnostic yield of early-onset mitochondrial disor-
ders using next-generation sequencing can be as high
as 60%, there remains a considerable proportion of
cases without a diagnosis. Similarly, we initially pri-
oritized autosomal recessive candidate variants based
on the decreased complex I and IV activities in pa-
tient’s skeletal muscle and an unremarkable family
history. Although the respiratory chain defects due
to the pathogenic CTBP1 variant are a likely second-
ary consequence, our experience suggests that this by
no means precludes the identification of pathogenic
variants in nonmitochondrial disease genes or an
autosomal dominant etiology.
The identification of a recurrent pathogenic de
novo c.991C.T p.(Arg331Trp) CTBP1 variant
using WES in a patient with decreased complex I
and IV activities serves to caution that inheritance
of suspected early-onset mitochondrial disorders
could wrongly be assumed autosomal recessive. Fur-
thermore, possible identification of patients with
respiratory chain defects due to variants involving
“non-classical mitochondrial disease” genes should
not be overlooked.6,7 Our observations suggest that
pathogenic de novo heterozygous variants could be
under-recognized in suspected early-onset mitochon-
drial disease, emphasizing the need to evaluate het-
erozygous variants with segregation studies in
apparently unsolved and prospective cases.
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